Moreover, administration of a neutralizing anti-IL-17RB antibody (50 μg/injection twice a week) did not affect MCF7-hIL-17B and MDA-MB-468-hIL-17B tumor progression in the absence of paclitaxel treatment (Figure 5A and 5B). Here, IL17RB is linked to neoplasm.